JP7502299B2 - 置換キサンチン誘導体 - Google Patents

置換キサンチン誘導体 Download PDF

Info

Publication number
JP7502299B2
JP7502299B2 JP2021533340A JP2021533340A JP7502299B2 JP 7502299 B2 JP7502299 B2 JP 7502299B2 JP 2021533340 A JP2021533340 A JP 2021533340A JP 2021533340 A JP2021533340 A JP 2021533340A JP 7502299 B2 JP7502299 B2 JP 7502299B2
Authority
JP
Japan
Prior art keywords
mmol
mixture
added
esi
hplc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021533340A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022512373A (ja
JP2022512373A5 (https=
Inventor
カイ ゲルラッハ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hydra Biosciences LLC
Original Assignee
Hydra Biosciences LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hydra Biosciences LLC filed Critical Hydra Biosciences LLC
Publication of JP2022512373A publication Critical patent/JP2022512373A/ja
Publication of JP2022512373A5 publication Critical patent/JP2022512373A5/ja
Application granted granted Critical
Publication of JP7502299B2 publication Critical patent/JP7502299B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021533340A 2018-12-12 2019-12-10 置換キサンチン誘導体 Active JP7502299B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18212060.0 2018-12-12
EP18212060 2018-12-12
PCT/EP2019/084375 WO2020120450A1 (en) 2018-12-12 2019-12-10 Substituted xanthine derivatives

Publications (3)

Publication Number Publication Date
JP2022512373A JP2022512373A (ja) 2022-02-03
JP2022512373A5 JP2022512373A5 (https=) 2022-12-16
JP7502299B2 true JP7502299B2 (ja) 2024-06-18

Family

ID=64665184

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021533340A Active JP7502299B2 (ja) 2018-12-12 2019-12-10 置換キサンチン誘導体

Country Status (18)

Country Link
US (2) US11198696B2 (https=)
EP (1) EP3894410B1 (https=)
JP (1) JP7502299B2 (https=)
KR (1) KR102877857B1 (https=)
CN (1) CN113166151B (https=)
AU (1) AU2019396499B2 (https=)
BR (1) BR112021008316A2 (https=)
CL (1) CL2021001509A1 (https=)
DK (1) DK3894410T3 (https=)
EA (1) EA202191588A1 (https=)
ES (1) ES2964630T3 (https=)
HU (1) HUE064908T2 (https=)
IL (1) IL283768B2 (https=)
MX (1) MX2021007019A (https=)
PH (1) PH12021551345A1 (https=)
PL (1) PL3894410T3 (https=)
TW (1) TWI825243B (https=)
WO (1) WO2020120450A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12064917B2 (en) 2012-11-21 2024-08-20 Stratasys, Inc. Method for printing three-dimensional parts with cyrstallization kinetics control

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE064908T2 (hu) * 2018-12-12 2024-04-28 Boehringer Ingelheim Int Szubsztituált xantinszármazékok
WO2024164818A1 (zh) * 2023-02-08 2024-08-15 中国科学院上海药物研究所 黄嘌呤类化合物及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016513717A (ja) 2013-03-15 2016-05-16 ハイドラ バイオサイエンシズ インコーポレイテッドＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． 置換キサンチンおよびその使用方法
JP2017523229A (ja) 2014-08-11 2017-08-17 ハイドラ バイオサイエンシズ インコーポレイテッドＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． ピリド［２，３−ｄ］ピリミジン−２，４（１Ｈ，３Ｈ）−ジオン誘導体
WO2018146485A1 (en) 2017-02-09 2018-08-16 University Of Leeds Trpc ion channel inhibitors for use in therapy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3652176T3 (da) * 2017-07-11 2022-01-17 Boehringer Ingelheim Int Substituerede xanthinderivater
HUE064908T2 (hu) * 2018-12-12 2024-04-28 Boehringer Ingelheim Int Szubsztituált xantinszármazékok

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016513717A (ja) 2013-03-15 2016-05-16 ハイドラ バイオサイエンシズ インコーポレイテッドＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． 置換キサンチンおよびその使用方法
JP2017523229A (ja) 2014-08-11 2017-08-17 ハイドラ バイオサイエンシズ インコーポレイテッドＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． ピリド［２，３−ｄ］ピリミジン−２，４（１Ｈ，３Ｈ）−ジオン誘導体
WO2018146485A1 (en) 2017-02-09 2018-08-16 University Of Leeds Trpc ion channel inhibitors for use in therapy

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12064917B2 (en) 2012-11-21 2024-08-20 Stratasys, Inc. Method for printing three-dimensional parts with cyrstallization kinetics control

Also Published As

Publication number Publication date
IL283768A (en) 2021-07-29
IL283768B2 (en) 2024-05-01
HUE064908T2 (hu) 2024-04-28
US11198696B2 (en) 2021-12-14
DK3894410T3 (da) 2023-11-27
TWI825243B (zh) 2023-12-11
AU2019396499B2 (en) 2024-10-10
WO2020120450A1 (en) 2020-06-18
KR102877857B1 (ko) 2025-10-29
CA3119229A1 (en) 2020-06-18
CL2021001509A1 (es) 2021-12-17
KR20210102955A (ko) 2021-08-20
BR112021008316A2 (pt) 2021-08-03
CN113166151B (zh) 2023-12-01
EP3894410A1 (en) 2021-10-20
PH12021551345A1 (en) 2022-05-11
JP2022512373A (ja) 2022-02-03
CN113166151A (zh) 2021-07-23
US20200190093A1 (en) 2020-06-18
MX2021007019A (es) 2021-09-10
ES2964630T3 (es) 2024-04-08
EA202191588A1 (ru) 2021-10-18
PL3894410T3 (pl) 2024-03-18
US20220177479A1 (en) 2022-06-09
EP3894410B1 (en) 2023-10-11
IL283768B1 (en) 2024-01-01
AU2019396499A1 (en) 2021-05-27
TW202039495A (zh) 2020-11-01

Similar Documents

Publication Publication Date Title
JP7114702B2 (ja) 新規置換キサンチン誘導体
CA3203285A1 (en) Heteroaryl carboxamide compound
JP7502299B2 (ja) 置換キサンチン誘導体
US12291532B2 (en) Substituted xanthines as modulators of TRPC5 activity
CA3119229C (en) Substituted xanthine derivatives
EA043969B1 (ru) Замещенные ксантиновые производные
BR112019025611B1 (pt) Compostos derivados de xantina substituídos e sais dos mesmos
HK40025200B (en) Substituted xanthine derivatives
HK40025200A (en) Substituted xanthine derivatives

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221208

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221208

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231110

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240216

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240507

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240606

R150 Certificate of patent or registration of utility model

Ref document number: 7502299

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150